Screening for PAH in patients with systemic sclerosis: focus on Doppler echocardiography.
It is well established that patients with CTDs such as SSc carry a considerable risk of developing pulmonary arterial hypertension (PAH). Such SSc-PAH patients have an even worse prognosis than patients with only one of these two conditions. In view of the high incidence and prevalence of PAH in SSc, and the available treatment options that improve quality of life, exercise capacity and possibly survival, systematic screening has been recommended. The present article reviews current recommendations from PAH guidelines, focusing on studies that used Doppler echocardiography for screening, and describes limitations associated with the procedure. Furthermore, characteristics and parameters used to identify patients at high risk of developing PAH are summarized.
Sánchez-Román
J
J
Collagenosis and Pulmonary Hypertension Unit, University Hospital Virgen delRocío, Seville, Spain. sanchezroman@nacom.es
Opitz
C F
CF
Kowal-Bielecka
O
O
García-Hernández
F J
FJ
Castillo-Palma
M J
MJ
Pittrow
D
D
D006328:Cardiac Catheterization; D015150:Echocardiography, Doppler; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000000981:diagnostic imaging*; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012595:Scleroderma, Systemic / Q000150:complications / Q000000981:diagnostic imaging*